Navigation Links
XenoTech Plans Expansion to New Global Headquarters after Impressive Revenue Growth in 2014

Lenexa, KS (PRWEB) April 21, 2015

Contract Research Organization XenoTech, LLC, a division of Sekisui, has announced plans to relocate into a new 41,500 ft2 facility. The planned move will double the size of XenoTech’s global headquarters, currently located at 16825 W. 116th St. in Lenexa, KS. The new facility, boasting nearly two and a half times the customized laboratory space, will remain in the Kansas City metro area, just blocks away from where the company was founded more than twenty years ago. Remaining in the Kansas City area maintains the company’s central location, ideal for quick access to both the East and West coasts of the United States. XenoTech is expected to complete the move into the new global headquarters in late fall, 2015.

XenoTech’s new location will serve as the global headquarters for their contract research business, providing the space necessary for an expanding range of services covering discovery through clinical support. XenoTech’s world-renowned in vitro products will continue to be produced within the new headquarters and will be used to support the contract research business conducted on-site. “XenoTech provides a variety of in vitro products and reagents to companies worldwide. We are known for our world-class services, but our in-house manufacturing of products not only helps to facilitate our global customers’ internal research efforts, but also provides the solid foundation behind our in vitro ADME / DDI service expertise. Our products are distributed in over 25 countries worldwide and we have a product catalog more than 90 pages long,” said Christian Darabant, VP of Commercial Operations.

XenoTech experienced impressive growth during fiscal year 2014, seeing record bookings and a greater than 15% increase in revenue over 2013. This growth was not only fuelled by an increasing demand for the company’s core ADME / DMPK / DDI expertise but also an ongoing expansion of related products and services designed to maximize convenience, study consistency and efficiency for XenoTech’s customers. This has resulted in an increase in the company’s client base and demand for the company’s products and services, requiring additional employees and an expanded facility.

XenoTech COO, Jason Neat, explained, “Relocating our headquarters both facilitates and compliments XenoTech’s dedication to expanding into natural extensions of our core ADME business. We take our reputation within the in vitro ADME-DMPK market very seriously, and we will not lose sight of our core expertise. Instead, this move allows us to grow naturally into complementing areas around our DMPK expertise, expanding our offerings to match the needs of our customers to reduce the time, expense and headache involved in bringing a drug to market.”

“XenoTech’s vision is to be the world’s foremost facilitator in the pursuit of life-enhancing therapies, and we are one step closer to that goal with the expansion into our new building. We will use the new space to drive scientific innovation and expand our offerings to ensure clients the quality they have come to expect from XenoTech, in a wider array of services, at even more attractive timelines,” added Neat.

The relocation also provides benefits to the Kansas City, KS community. XenoTech hired 11 full-time staff members over the course of 2014 and is planning continued expansion of its workforce throughout the next few years. XenoTech employees bring a community-focused outlook to the region and have raised nearly $250,000 in charitable donations and given countless hours of personal time towards community outreach and philanthropic events.

About XenoTech
XenoTech, LLC is a global Contract Research Organization with unparalleled experience and proven expertise from discovery through clinical support, providing cell and tissue-based products, screening, radiolabeling, API manufacturing, in vitro ADMET and pharmacology, in vivo ADMET and QWBA, metabolite ID and production, bioanalytical services and consulting. XenoTech's product selection includes a wide-range of high quality standard reagents, from subcellular fractions and hepatocytes to recombinant enzymes, substrates and metabolites. The company also regularly prepares and delivers custom-designed products and services in response to client requests. For additional information, please refer to the company's website at or call your local XenoTech representative.

Read the full story at

Source: PRWeb
Copyright©2015 Vocus, Inc.
All rights reserved

Related biology technology :

1. Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech
2. Regenestem Network Announces Plans to Attend the 23rd Annual World Congress on Anti-Aging Medicine May 7-9, 2015
3. Metabolic Solutions Development Company Highlights Plans for MSDC-0602 in NASH and Polycystic Kidney Disease
4. CytoSorbents Plans Robust Agenda at ISICEM 2015
5. DuPont Leader Highlights Strategy, Progress and Plans to Accelerate Growth in Advanced Materials and Discusses Near-Term Outlook
6. ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015
7. DuPont Pioneer, Perdue AgriBusiness Announce Plans to Double Acreage for the 2015 Plenish® High Oleic Soybean Program
8. OXIS International announces plans to Enter the Cannabis Biotech Sector, Completion of Financing, Changes to the Board of Directors
9. Telik Announces Plans for Special Meeting of Stockholders and Transition to MabVax Therapeutics Holdings, Inc.
10. United Technologies plans $10 million investment for UConn systems engineering institute
11. National Brain Tumor Society Announces the Defeat GBM Research Collaborative’s Project Plans and Investigator Teams
Post Your Comments:
(Date:6/11/2019)... Fla. (PRWEB) , ... June 10, 2019 , ... ... in science and technology in an upcoming episode, scheduled to broadcast 4Q/2019. Check ... the Eppendorf Group) and will educate viewers about how its technology facilitates laboratories ...
(Date:6/11/2019)... ... June 11, 2019 , ... Mytonomy, ... a national leader in opioid treatment, announced today they are partnering to combat ... Mytonomy recently deployed its virtual care platform at the Mayo Clinic to drive ...
(Date:6/11/2019)... ... June 11, 2019 , ... A study released ... cells (MSC-EV) are able to incorporate into human CD34+ cells, modifying their gene ... MSC-EVs also increased the cells’ ability to lodge into bone marrow. This research ...
(Date:5/31/2019)... ... May 29, 2019 , ... For many years, the primary forms of cancer ... breakthrough therapies. Advances in immuno-oncology have led to the advent of Chimeric Antigen Receptor ... T cell receptors known as “CARs”. The CAR enables the final product to produce ...
Breaking Biology Technology:
(Date:7/17/2019)... ... ... Imagine using a simple, portable test to detect cancer before malignant tissues ... South Dakota School of Mines & Technology researcher Congzhou Wang, Ph.D., these ideas are ... to monitor and prevent disease,” says Wang. , Wang, an assistant professor in ...
(Date:7/9/2019)... (PRWEB) , ... July 08, 2019 , ... ... ruled in favor of Danisco’s ownership of the innovation behind two Danisco amylase ... an entitlement action could be based on prior art was without merit and ...
(Date:6/20/2019)... ... June 19, 2019 , ... The half-million dollars ... of America Foundation, and the possibly millions of dollars of “high priority” grants ... AD, are a “welcome affirmation” of the need to investigate more thoroughly the ...
Breaking Biology News(10 mins):